CorMedix Inc. to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 11
May 04 2020 - 9:00AM
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company
focused on developing and commercializing therapeutic products for
the prevention and treatment of infectious and inflammatory
disease, today announced that it will report its financial results
for the first quarter ended March 31, 2020, after the market close
on Monday, May 11, and will host a corporate update conference call
at 4:30pm Eastern Time.
Monday, May
11th @ 4:30pm ET |
Domestic: |
800-949-2175 |
International: |
646-828-8144 |
Conference ID: |
3381536 |
Webcast: |
http://public.viavid.com/index.php?id=139349 |
About CorMedix
CorMedix Inc. is a biopharmaceutical company
focused on developing and commercializing therapeutic products for
the prevention and treatment of infectious and inflammatory
diseases. The Company is focused on developing its lead product
Neutrolin®, a novel, non-antibiotic antimicrobial solution designed
to prevent costly and dangerous bloodstream infections associated
with the use of central venous catheters for the U.S. market. The
Company completed a Phase 3 clinical trial of Neutrolin in patients
undergoing chronic hemodialysis, which showed a 71% reduction in
catheter-related bloodstream infections (CRBSIs) relative to the
heparin control arm (p=0.0006) with a good safety profile. Such
infections cost the U.S. healthcare system approximately $6 billion
annually and contribute significantly to increased morbidity and
mortality. Neutrolin has FDA Fast Track status and is designated as
a Qualified Infectious Disease Product, which provides the
potential for priority review of a marketing application by FDA and
allows for 5 additional years of QIDP market exclusivity in the
event of U.S. approval. FDA has granted rolling submission
and review of portions of the new drug application (NDA) and
CorMedix has begun submission of the NDA. Neutrolin is already
marketed as a CE Marked product in Europe and other territories. In
parallel, CorMedix is leveraging its taurolidine technology to
develop a pipeline of antimicrobial medical devices, with active
programs in surgical sutures and meshes, and topical
hydrogels. The company is also working with top-tier
researchers to develop taurolidine-based therapies for rare
pediatric cancers. For more information, visit:
www.cormedix.com.
Investor Contact:Dan FerryManaging
DirectorLifeSci Advisors617-430-7576
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Sep 2023 to Sep 2024